Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06709339 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

Study acronym: MONDEGO
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 15 of 31 sitesv5
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 26 to 31
    • Primary and study completion dates: Apr 2028 to Aug 2028
    • Start date changed from estimate of Jun 2025 to Aug 6, 2025
    • Eligibility criteria expanded, about 266 words
  3. Start date: Apr 2025 to Jun 2025v3
  4. Study description shortened, about 2 words
    • Study title shortened, about 3 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to assess the efficacy, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV). The main question it aims to answer is: To evaluate the efficacy of intravitreal (IVT) injections of faricimab 6 milligrams (mg) on Best Corrected Visual Acuity (BCVA) outcomes in caucasian patients with symptomatic macular PCV. Participants will undergo ophthalmic examination, safety assessment and treatment with faricimab according to a patient specific treat and extend regimen.
Trial Details
NCT Number NCT06709339
Lead Sponsor Association for Innovation and Biomedical Research on Light and Image
Conditions
(from sponsor)		 Polypoidal Choroidal Vasculopathy
Related terms Polypoidal Choroidal Vasculopathy
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov